← Back to Screener
Werewolf Therapeutics, Inc. Common Stock (HOWL)
Price$0.91
Favorite Metrics
Price vs S&P 500 (26W)-55.07%
Price vs S&P 500 (4W)3.25%
Market Capitalization$44.69M
All Metrics
Book Value / Share (Quarterly)$0.51
P/TBV (Annual)0.71x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.24
Price vs S&P 500 (YTD)42.52%
Net Profit Margin (TTM)-578.67%
EPS (TTM)$-1.32
10-Day Avg Trading Volume0.37M
EPS Excl Extra (TTM)$-1.32
EPS (Annual)$-1.30
ROI (Annual)-114.67%
Cash / Share (Quarterly)$1.17
ROA (Last FY)-87.64%
EBITD / Share (TTM)$-1.22
ROE (5Y Avg)-90.31%
Operating Margin (TTM)-634.15%
Cash Flow / Share (Annual)$-1.24
P/B Ratio1.80x
P/B Ratio (Quarterly)1.24x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)1.71x
Net Interest Coverage (TTM)-27.08x
ROA (TTM)-69.75%
EPS Incl Extra (Annual)$-1.30
Current Ratio (Annual)1.62x
Quick Ratio (Quarterly)1.58x
3-Month Avg Trading Volume0.54M
52-Week Price Return19.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.15
P/S Ratio (Annual)23.71x
Asset Turnover (Annual)0.01x
52-Week High$2.38
EPS Excl Extra (Annual)$-1.30
CapEx CAGR (5Y)-1.21%
26-Week Price Return-51.09%
Quick Ratio (Annual)1.58x
13-Week Price Return60.04%
Total Debt / Equity (Annual)1.14x
Current Ratio (Quarterly)1.62x
Enterprise Value$15.876
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3740.85%
Cash / Share (Annual)$1.17
3-Month Return Std Dev94.21%
Net Income / Employee (TTM)$-2
ROE (Last FY)-245.20%
Net Interest Coverage (Annual)-27.08x
EPS Basic Excl Extra (Annual)$-1.30
Receivables Turnover (TTM)5.04x
Total Debt / Equity (Quarterly)1.14x
EPS Incl Extra (TTM)$-1.32
ROI (TTM)-92.59%
P/S Ratio (TTM)4.81x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.89
Price vs S&P 500 (52W)-10.68%
Year-to-Date Return45.16%
5-Day Price Return2.36%
EPS Normalized (Annual)$-1.30
ROA (5Y Avg)-45.21%
Net Profit Margin (Annual)-3740.85%
Month-to-Date Return10.45%
Cash Flow / Share (TTM)$-1.04
EBITD / Share (Annual)$-1.22
Operating Margin (Annual)-3933.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-57.41%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.32
P/TBV (Quarterly)0.78x
P/B Ratio (Annual)1.24x
Pretax Margin (TTM)-578.67%
Book Value / Share (Annual)$0.51
Price vs S&P 500 (13W)59.35%
Beta0.59x
Revenue / Share (TTM)$0.00
ROE (TTM)-158.81%
52-Week Low$0.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.27
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HOWLWerewolf Therapeutics, Inc. Common Stock | 4.81x | — | — | — | $0.91 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Werewolf Therapeutics develops cancer immunotherapies using its proprietary PREDATOR platform to engineer conditionally activated molecules. The company's INDUKINE molecules remain inactive in healthy tissue but selectively activate immune responses within the tumor microenvironment, potentially addressing the side-effect limitations of conventional immunotherapies. This targeted approach aims to combine improved therapeutic efficacy with reduced systemic toxicity.